|
May 29
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
May 28
|
Halozyme to Participate at Upcoming Investor Conferences
|
|
May 28
|
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
|
|
May 28
|
Implied Volatility Surging for Halozyme Therapeutics Stock Options
|
|
May 28
|
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
|
|
May 28
|
High Growth Tech Stocks To Watch In The US May 2025
|
|
Apr 16
|
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity
|
|
Mar 13
|
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
|
|
Mar 13
|
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 11
|
HALO vs. AMGN: Which Stock Is the Better Value Option?
|
|
Mar 10
|
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why
|
|
Mar 7
|
AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.
|
|
Mar 6
|
High Growth Tech Stocks To Watch In US March 2025
|
|
Mar 6
|
Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version
|
|
Mar 5
|
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
|
|
Mar 5
|
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
|
|
Mar 5
|
Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version
|
|
Feb 26
|
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
|
|
Feb 13
|
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
|
|
Feb 13
|
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
|